NASDAQ:NRXS NeurAxis (NRXS) Stock Price, News & Analysis $6.86 +0.11 (+1.63%) Closing price 04:00 PM EasternExtended Trading$6.87 +0.01 (+0.15%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About NeurAxis Stock (NASDAQ:NRXS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NeurAxis alerts:Sign Up Key Stats Today's Range$6.77▼$7.0750-Day Range$6.67▼$8.3552-Week Range$2.20▼$9.33Volume20,185 shsAverage Volume141,502 shsMarket Capitalization$84.95 millionP/E RatioN/ADividend YieldN/APrice Target$13.00Consensus RatingBuy Company Overview NeurAxis (NASDAQ: NRXS) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic candidates for diseases of the central nervous system. The company leverages a proprietary approach to deliver small molecules and biologics across the blood–brain barrier, aiming to address conditions ranging from acute neural injury to chronic neurodegenerative disorders. NeurAxis advances its pipeline through a combination of in-house research, external collaborations with academic medical centers and contract research organizations, and strategic licensing agreements. Its lead programs are designed to modulate key pathways involved in neuronal survival and regeneration, with preclinical and early-stage clinical studies underway to assess safety, pharmacokinetics and proof of concept. Headquartered in the United States, NeurAxis engages with international partners to support its translational and clinical development activities. The company’s common shares trade on the Nasdaq Stock Market under the ticker symbol NRXS.AI Generated. May Contain Errors. Read More NeurAxis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreNRXS MarketRank™: NeurAxis scored higher than 28% of companies evaluated by MarketBeat, and ranked 722nd out of 840 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNeurAxis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Upside PotentialNeurAxis has a consensus price target of $13.00, representing about 89.5% upside from its current price of $6.86.Amount of Analyst CoverageNeurAxis has received no research coverage in the past 90 days.Read more about NeurAxis' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of NeurAxis is -3.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeurAxis is -3.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about NeurAxis' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for NRXS. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeurAxis does not currently pay a dividend.Dividend GrowthNeurAxis does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows1 people have added NeurAxis to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NeurAxis insiders have not sold or bought any company stock.Percentage Held by Insiders21.10% of the stock of NeurAxis is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions11.77% of the stock of NeurAxis is held by institutions.Read more about NeurAxis' insider trading history. Receive NRXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeurAxis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NRXS Stock News HeadlinesNeurAxis Declares Q2 Stock Dividend on Series BJuly 10, 2026 | tipranks.comNeuraxis (NRXS) Stock Forecast & Price TargetJune 17, 2026 | investing.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.July 20 at 1:00 AM | Profits Run (Ad)NeurAxis Stockholders Approve Directors and Equity Compensation PlansJune 12, 2026 | tipranks.comNeurAxis Earnings Call Highlights Growth and HurdlesMay 22, 2026 | theglobeandmail.comNeurAxis (NRXS) Climbs on Reimbursement and Guideline MomentumMay 18, 2026 | insidermonkey.comNeurAxis Stock Gains Post Q1 Earnings, Revenues and Margin Surge Y/YMay 15, 2026 | finance.yahoo.comNeurAxis, Inc. (NRXS) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comSee More Headlines NRXS Stock Analysis - Frequently Asked Questions How have NRXS shares performed this year? NeurAxis' stock was trading at $4.54 at the start of the year. Since then, NRXS shares have increased by 51.1% and is now trading at $6.86. How were NeurAxis' earnings last quarter? NeurAxis, Inc. (NASDAQ:NRXS) announced its earnings results on Tuesday, November, 12th. The company reported ($0.25) earnings per share (EPS) for the quarter. The company had revenue of $0.67 million for the quarter. When did NeurAxis IPO? NeurAxis (NRXS) raised $7 million in an IPO on Wednesday, August 9th 2023. The company issued 1,098,667 shares at $6.00 per share. How do I buy shares of NeurAxis? Shares of NRXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NeurAxis own? Based on aggregate information from My MarketBeat watchlists, some other companies that NeurAxis investors own include AutoZone (AZO), Intel (INTC), Meta Platforms (META), Outdoor (POWW), SPDR S&P 500 ETF Trust (SPY), TJX Companies (TJX) and ETRACS Crude Oil Shares Covered Call ETN (USOI). Company Calendar Last Earnings11/12/2024Today7/20/2026Next Earnings (Estimated)9/17/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryMedical Equipment Current SymbolNASDAQ:NRXS CIK1933567 Webneuraxis.com Phone(812) 689-0791FaxN/AEmployees19Year Founded2011Price Target and Rating Average Price Target for NeurAxis$13.00 High Price Target$13.00 Low Price Target$13.00 Potential Upside/Downside+89.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($0.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.63 million Net Margins-492.76% Pretax Margin-341.35% Return on EquityN/A Return on Assets-641.25% Debt Debt-to-Equity RatioN/A Current Ratio0.24 Quick Ratio0.23 Sales & Book Value Annual Sales$4.28 million Price / Sales19.84 Cash FlowN/A Price / Cash FlowN/A Book Value($0.27) per share Price / Book-25.41Miscellaneous Outstanding Shares12,384,000Free Float6,085,000Market Cap$84.95 million OptionableNot Optionable Beta1.43 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:NRXS) was last updated on 7/20/2026 by MarketBeat.com Staff. From Our PartnersBacked Company Could Save Power GridA small Colorado company holds the rights to technology that could protect the U.S. public power grid from col...Altimetry | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredNVIDIA offered $40B. The answer was no.Apple, NVIDIA, Google, Amazon, and Samsung all pay one company billions in royalties every year. NVIDIA tried ...Behind the Markets | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredTrump is positioned. Elon lights the fuse.Earlier this year, the Trump-backed World Liberty Trust applied for a federal banking charter. Now, new report...Crypto 101 Media | SponsoredWhen governments buy their own debt, gold miners moveOn April 16th, the U.S. Treasury executed a $15 billion buyback of its own debt - the largest in history - whi...Golden Portfolio | SponsoredWhere to Put $100 Before Trump's New Tech Law Rolls OutThe Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeurAxis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeurAxis With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
